Integrin beta3 as a therapeutic target for breast cancer metastasis to bone

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/509131

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

There are limited effective treatments for advanced breast cancer. The project investigates the role of a protein called integrin beta3 in the spread of breast tumours to bone, the most common site of secondary tumour formation (metastasis) in breast cancer patients. We will determine if the presence of integrin beta3 in breast tumours identifies patients at risk of developing bone metastases and test novel drugs against integrin beta3 in mice.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2010

Funding Scheme: NHMRC Project Grants

Funding Amount: $431,675.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology And Carcinogenesis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Anti-cancer drugs | Breast Cancer | Breast cancer metastases | Cancer prognosis | Cancer-induced osteolysis | Mouse models of cancer | Murine models | Prognosis | Therapy of breast cancer | Tumour metastases

Related Links